Krystal Biotech, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 4.37M | $1.13B | 0.06% | Added+0.6% | 2026-03-31 |
| StateStreet | passive | 1.31M | $339.54M | 0.01% | Trimmed-2.1% | 2026-03-31 |
| Bridgewater | macro | 46.4K | $11.98M | 0.05% | Added+363.0% | 2026-03-31 |
| Wellington | fundamental | 10.2K | $2.64M | 0.00% | Trimmed-4.0% | 2026-03-31 |
| RenTech | quant | 9.6K | $2.48M | 0.00% | Added+190.9% | 2026-03-31 |
| DEShaw | quant | 996 | $257.29K | 0.00% | Trimmed-52.8% | 2026-03-31 |
| TRowePrice | fundamental | 485.1K | $125.31K | 0.01% | Trimmed-8.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | 1.94 | — | — |
| 2026-05-04 | 1.44 | 1.83 | +27.30% |
| 2026-02-17 | 1.61 | 1.70 | +5.81% |
| 2025-11-03 | 1.09 | 2.66 | +144.88% |
| 2025-08-04 | 1.44 | 1.29 | -10.15% |
| 2025-05-06 | 1.37 | 1.20 | -12.17% |
| 2025-02-19 | 1.19 | 1.53 | +28.57% |
| 2024-11-04 | 1.33 | 1.29 | -3.18% |
| 2024-08-05 | 0.99 | 0.93 | -5.88% |
| 2024-05-06 | 0.29 | 0.46 | +58.14% |
| 2024-02-26 | -0.25 | 0.96 | +479.17% |
| 2023-11-06 | -0.67 | -0.67 | +0.75% |
| 2023-08-07 | -0.74 | -1.25 | -69.68% |
| 2023-05-08 | -1.37 | -1.76 | -28.84% |
| 2023-02-27 | -0.56 | -1.25 | -121.89% |
| 2022-11-07 | -1.26 | -1.17 | +6.96% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| KRYS | +16.16% | +17.15% | +25.35% | +145.34% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +13.19% | +21.78% | +28.79% | +132.65% |